Why Climate Never Got Its Own Biotech Moment
October 2, 2026
In the summer of 2025, Royalty Pharma committed up to $2 billion to Revolution Medicines for a single asset: a cancer drug called daraxonrasib that,
In the summer of 2025, Royalty Pharma committed up to $2 billion to Revolution Medicines for a single asset: a cancer drug called daraxonrasib that,
Nearly 700 medicines approved for use in the United States depend on at least one chemical produced solely in China, according to United States Pharmacopeia
